Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 11752137 Ophthalmic compositions for treating ocular

Patent 11752137 was granted and assigned to Tarsus Pharmaceuticals on September, 2023 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity
Is a
Patent
Patent
Current Assignee
Tarsus Pharmaceuticals
Tarsus Pharmaceuticals
Date Filed
July 26, 2022
Date of Patent
September 12, 2023
Patent Applicant
Tarsus Pharmaceuticals
Tarsus Pharmaceuticals
Patent Application Number
17873698
Patent Citations
‌
US Patent 7964204 Isoxazolines for controlling invertebrate pests
‌
US Patent 8022089 Isoxazoline-substituted benzamide compound and pesticide
‌
US Patent 8128968 Compositions and methods for treating
‌
US Patent 8138213 Isoxazoline-substituted benzamide compound and pesticide
‌
US Patent 8207206 (S,R)-3-phenyl-4,5 dihydro-5-isoxazole acetic acid-nitric oxide and use thereof as anti-cancer and antiviral agent
‌
US Patent 7348317 Aqueous compositions containing metronidazole
‌
US Patent 7531186 Topical formulations comprising 1-N-arylpyrazole derivatives and amitraz
‌
US Patent 7662972 Isoxazoline-substituted benzamide compound and pesticide
‌
US Patent 7906128 Use of neuronal sodium channel antagonists for the control of ectoparasites in homeothermic animals
‌
US Patent 7906130 Amitraz compositions
•••
Patent Inventor Names
Bobak Robert Azamian
Joseph G. Vehige
Shawn D. Hickok
Douglas Michael Ackermann
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
11752137
Patent Primary Examiner
‌
Shengjun Wang
CPC Code
‌
A61K 9/0048
‌
A61P 27/02
‌
A61P 33/14
‌
A61K 31/422

Find more entities like US Patent 11752137 Ophthalmic compositions for treating ocular

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo